(Reuters) - GPC said the FDA's Oncologic Drugs Advisory Committee will review satraplatin on July 24 and action from the FDA on the cancer drug is expected in August.
GPC said on Tuesday sales in the first quarter were 3.8 million euros, 25 percent lower than in the fourth quarter of 2006 and down 30 percent year on year.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment